BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Human chorionic gonadotropin
,
Fenofibrate
,
rs3825942
,
TGFB1
,
HIV infection
,
Intestine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TSC1
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Cerebellum
Cingulate cortex
Cerebellar hemisphere
Substantia nigra pars compacta
Prefrontal cortex
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Newly identified tumor suppressor functions of ING proteins.
Merlin tumor suppressor function is regulated by PIP2-mediated dimerization.
MUM1L1 as a Tumor Suppressor and Potential Biomarker in Ovarian Cancer: Evidence from Bioinformatics…
Structure of putative tumor suppressor ALDH1L1.
A rationalized definition of general tumor suppressor microRNAs excludes miR-34a.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Everolimus for Cancer With TSC1 or TSC2 Mutation
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Altera…
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/o…
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutation…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ